Supernus Pharmaceuticals, Inc. - Common Stock — Liquidità (NASDAQ:SUPN) | MetaTrader

Apri il grafico completo Full chart

Financials

Panoramica Estratto Conto Statistiche

Trimestrale Annuale

Flusso di cassa derivante dalle attività operative 138.4 M127.13 M116.83 M111.08 M171.95 M47.33 M 83.26 M Flussi di cassa derivanti dalle attività di investimento -34.7 M-81.91 M-216.66 M268.73 M-189.87 M4.11 M -52.43 M Liquidità derivante dalle attività di finanziamento 3.56 M-130.42 M-10.48 M397.88 M12.19 M9.13 M 39.64 M Liquidità libera 138.4 M127.13 M116.83 M111.08 M171.95 M45.99 M 82.25 M

Notizie

Should You Buy, Sell or Hold BIIB Stock After it Rises Almost 12% YTD?

Supernus Pharmaceuticals pagherà 33,4 milioni di dollari ai titolari di CVR

Supernus Pharmaceuticals, Inc. (SUPN) Presents at Bank of America Global Healthcare Conference 2026 Transcript

Supernus Pharmaceuticals, Inc. (SUPN) Q1 2026 Earnings Call Transcript

Supernus (SUPN) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates

Supernus Pharmaceuticals (SUPN) Beats Q1 Earnings and Revenue Estimates

Bausch Health (BHC) Lags Q1 Earnings Estimates

Biogen Beats Q1 Earnings Estimates but Cuts 2026 EPS View on M&A Costs

Biogen Walloped Wall Street's First Quarter Views; Here's What Happened

BofA riduce il target di prezzo di Supernus Pharmaceuticals per i costi

Biogen Q1 Earnings: Can New Launches Offset Declining MS Franchise?

Jefferies conferma il rating Buy su Supernus Pharmaceuticals